In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus medication litifilimab. In return, Royalty Pharma will receive undisclosed ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Sage Therapeutics has brought a lawsuit against ... to with Biogen,” a Sage spokesperson said in a statement to Fierce Pharma. The two firms joined hands in late 2020 when Biogen signed on ...

Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its board of directors has initiated a process to explore strategic alternatives ...

Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00.

Sage's board concluded the proposal "significantly ... Biogen,” a Sage spokesperson confirmed in a statement to Fierce Pharma last week. In the companies' original pact, Biogen agreed not ...

Inizio has announced that it has appointed Jim Sage as president of Inizio Engage. Sage holds more than 25 years of ...